Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
15 May 2007Website:
http://www.insulet.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:29:36 GMTDividend
Analysts recommendations
Institutional Ownership
PODD Latest News
Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Omnipod 5, compatible with both Dexcom G6 and Abbott FreeStyle Libre 2 Plus continuous glucose monitor (CGM) sensors, is now fully available in the U.K. and the Netherlands for individuals aged two years and older with type 1 diabetes. Omnipod 5 is the first and only tubeless automated insulin.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well.
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insulet's (PODD) strong first-quarter results are driven by the sustained high demand for Omnipod 5.
In addition to examining Wall Street's forecasts for Insulet (PODD), it is important to also analyze projections for its key performance indicators in order to better understand the company's performance in the first quarter of 2024.
Insulet (PODD) ended the latest trading session at $173.42, showing a 1.85% increase from the day before.
Investors can utilize the Zacks Style Scores to identify top-rated stocks that align with their investing style, making it a valuable tool to leverage.
What type of business is Insulet?
Insulet Corporation is a company that designs, manufactures, and commercializes medical devices for insulin therapy. Founded in 2000, the company's headquarters is located in Acton, Massachusetts. Insulet's focus is on the development, production, and sale of its patented Omnipod system - an innovative, discreet, and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod system provides continuous insulin delivery at a predetermined rate, eliminating the need for individual insulin injections. Additionally, insulin delivery can be adjusted with the push of a button to adapt to unexpected changes in a patient's daily schedule.
What sector is Insulet in?
Insulet is in the Healthcare sector
What industry is Insulet in?
Insulet is in the Medical Devices industry
What country is Insulet from?
Insulet is headquartered in United States
When did Insulet go public?
Insulet initial public offering (IPO) was on 15 May 2007
What is Insulet website?
https://www.insulet.com
Is Insulet in the S&P 500?
Yes, Insulet is included in the S&P 500 index
Is Insulet in the NASDAQ 100?
No, Insulet is not included in the NASDAQ 100 index
Is Insulet in the Dow Jones?
No, Insulet is not included in the Dow Jones index
When does Insulet report earnings?
The next expected earnings date for Insulet is 08 August 2024